Trial Profile
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Aplastic anaemia
- Focus Therapeutic Use
- 30 Sep 2020 Status changed from active, no longer recruiting to completed.
- 06 Nov 2019 Trial design released in the 61st Annual Meeting and Exposition of the American Society of Hematology
- 16 Apr 2019 Results assessing dosing, duration, long term outcomes and clonal evolution of Eltrombopag using 2 studies (NCT00922883 and NCT01891994) published in the Blood